An Observational Study Conducted in China to Evaluate the Efficacy and Safety of Darolutamide in Combination With Androgen Deprivation Therapy (ADT) for Men With Non-metastatic Prostate Cancer That Progressed Following Prior Bicalutamide + ADT Treatment

NCT07538843 | Not Yet Recruiting

• 1 other identifier: 23126
• Study Type: observational
• Target: 800
• Locations: 1 country
• Sites: 1

Brief Summary

In this observational study, participants receive darolutamide: a treatment that is already available for doctors to prescribe for non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic hormone-sensitive prostate cancer (mHSPC). Prostate cancer is a common cancer in men, and the number of cases is rising, especially in China. Many men are diagnosed at a late stage, which makes treatment more difficult. Standard treatment for prostate cancer often includes lowering the levels of male hormones (androgens) in the body, as these hormones can help the cancer grow. This is called androgen deprivation therapy (ADT). Sometimes, medicines like bicalutamide are added to ADT, but over time, the cancer can become resistant to these treatments. When this happens and the cancer has not yet spread to other parts of the body, it is called nmCRPC. Newer agents, such as darolutamide, have demonstrated efficacy in controlling the disease and delaying progression, with a more favorable safety profile and fewer severe adverse events than conventional therapies. This study wants to observe how effective darolutamide plus ADT is at controlling the cancer in Chinese men with nmCRPC who have already been treated with bicalutamide plus ADT during an earlier stage of their disease, known as non-metastatic hormone-sensitive prostate cancer (nmHSPC), but whose cancer has since progressed despite that treatment. The study will look at how many participants have their prostate-specific antigen (PSA) levels drop to undetectable levels within 6 months of starting darolutamide (in the main group of 800 participants). PSA is a protein made by the prostate, and high levels can be a sign of prostate cancer. In a smaller group of 100 participants, the study will also look at how many men remain free from PSA progression (a sign that the cancer is not getting worse) after 12 months. To learn more about the safety of darolutamide, the researchers will study whether the participants have adverse events. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments. The researchers will also learn more about how well darolutamide is working in these participants.

Conditions

Non-metastatic Castration-resistant Prostate Cancer

Outcome Measures

Primary Outcomes (2)

• Proportion of patients with prostatic specific antigen (PSA) undetectable within 6 months (Master Cohort)

  The proportion of patients with undetectable PSA at any time within the 6 months after treatment initiation, undetectable PSA is defined as an absolute PSA level \<0.2 ng/ml

  up to 6 months

• Proportion of patients with PSA Progression Free Survival (PSA-PFS) rate at 12 months (Sub-cohort)

  The proportion of patients who remain PSA progression free by 12 months. PSA progression: (i) PSA increase of≥ 25% and an absolute increase of≥2 ng/mL above the nadir, which is confirmed by a second value obtained 3 or more weeks later, in case of decline, or (ii) a PSA increase of≥25%, and an absolute increase of≥ 2 ng/mL after 12 weeks in case of no decline from the baseline.

  up to 12 months

Secondary Outcomes (9)

• Proportion of patients with PSA50 within 3 months (Master cohort)

  Up to 3 months

• Proportion of patients with PSA50 within 6 months (Master cohort)

  Up to 6 months

• Proportion of patients with PSA90 within 3 months (Master cohort)

  Up to 3 months

• Proportion of patients with PSA90 within 6 months (Master cohort)

  Up to 6 months

• Proportion of patients with PSA undetectable within 3 months (Master cohort)

  Up to 3 months

Study Arms (2)

Master-cohort (6 months follow-up)

Male patients receiving ADT+Bicalutamide for ≥ 6 months in non-metastatic hormone-sensitive prostate cancer (nmHSPC), that progressed to non-metastatic castration-resistant prostate cancer (nmCRPC)

Drug: Darolutamide; Drug: ADT

Sub-cohort (12 months follow-up)

Male patients receiving ADT+Bicalutamide for ≥ 6 months in non-metastatic hormone-sensitive prostate cancer (nmHSPC), that progressed to non-metastatic castration-resistant prostate cancer (nmCRPC)

Drug: Darolutamide; Drug: ADT

Interventions

Darolutamide DRUG

Darolutamide administered per local standard of care in combination with ADT.

Also known as: Nubeqa, BAY1841788

Master-cohort (6 months follow-up); Sub-cohort (12 months follow-up)

ADT DRUG

Androgen deprivation therapy administered per local standard of care.

Master-cohort (6 months follow-up); Sub-cohort (12 months follow-up)

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Male patients diagnosed with nmCRPC, as determined by their treating physician, fulfilling the inclusion and exclusion criteria

You may qualify if:

• Males Age ≥ 18 years.
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
• Patients receiving ≥6 m ADT+Bicalutamide in nmHSPC, progressed to nmCRPC judged by investigators.
• Serum testosterone level\<1.7 nmol/L.
• Decision to initiate treatment with ADT + Darolutamide as per investigator's routine treatment practice.
• No evidence of metastasis as assessed by computed tomography (CT)/magnetic resonance imaging (MRI) for soft tissue disease and whole-body radionuclide bone scan for bone disease.
• The informed consent form must be signed by the patient or his legal guardian (as applicable).
• Patients who are fertile must use an effective method of contraception during the study and must refrain from donating sperm during the study or for 3 months after the end of treatment, unless they have undergone a radical prostatectomy.

You may not qualify if:

• Participation in an investigational program with interventions outside of routine clinical practice.
• Presence of distant metastases, including involvement of the Central Nervous System (CNS) and vertebral or meningeal involvement.
• Symptomatic local or regional lesions requiring medical intervention (moderate or severe urinary tract obstruction or hydronephrosis caused by the primary tumor).
• Previous treatment with 2nd-generation ARIs.
• Previous treatment with CYP17 inhibitors.
• Previous treatment with radiopharmaceuticals, immunotherapy, or other investigational treatment for nmCRPC.
• Severe/unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events, or clinically significant ventricular arrhythmias.
• Gastrointestinal diseases affecting absorption.

Sponsors & Collaborators

• Bayer: lead

Study Sites (1)

Many locations

Multiple Locations, China

Location

MeSH Terms

Interventions

darolutamide

Central Study Contacts

Bayer Clinical Trials Contact

CONTACT

(+)1-888-84 22937; clinical-trials-contact@bayer.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 13, 2026
• First Posted: April 20, 2026
• Study Start (Estimated): June 1, 2026
• Primary Completion (Estimated): November 1, 2029
• Study Completion (Estimated): January 30, 2030
• Last Updated: April 20, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)